{"type":"trials","record":{"id":87201,"source_id":"isrctn","external_id":"ISRCTN16381123","title":"Randomised, placebo controlled, patient and observer masked study to evaluate the efficacy of treatment with Sandostatin® LAR 20 mg intramuscularly (i.m.) or placebo every 4 weeks during 6 months in 120 patients with exudative age-related macular degeneration","brief_summary":"Sandostatin® LAR administered intramuscularly (i.m.) at a dose of 20 mg once per 4 weeks during 6 months, to patients with exudation in age-related macular degeneration (AMD), maintains stable visual acuity, and decreases macular oedema and neovascularisation.","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)","enrollment":120,"countries":["Netherlands"],"start_date":"2000-02-02","completion_date":"2003-08-21","last_update_date":"2008-11-04","source_url":"https://www.isrctn.com/ISRCTN16381123","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN16381123; retrieved 2026-09-25","interventions":["Sandostatin® LAR","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["1. Visual acuity and contrast sensitivity 2. Decrease in macular oedema 3. Arrest of neovascularisation (FAG)","No secondary outcome measures"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Exudative age-related macula degeneration (AMD)","Intramuscular injection of 20 mg Sandostatin® LAR or standard 0.9% saline solution once every 4 weeks during 6 months.","Sandostatin® LAR","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn16381123","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2000-02-02 to 2003-08-21","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.601Z","intervention":["Sandostatin® LAR","Drug"],"participants":120,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["1. Visual acuity and contrast sensitivity 2. Decrease in macular oedema 3. Arrest of neovascularisation (FAG)","No secondary outcome measures"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87201","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}